Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Journey Genomics S L has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution involves 1 distinct examiner and 1 distinct art unit. This concentration suggests a specialized focus for the applicant's current intellectual property development. By working with 1 examiner, the company can maintain a consistent dialogue regarding its technical innovations in the biotechnology sector.
The busiest examiner, SMITH, EMILIE ALINE, is assigned 1 busiest examiner pending office action. As the total number of pending office actions is 1, SMITH, EMILIE ALINE handles the active prosecution for the company. The success of the applicant's current filings depends on navigating the specific examination criteria of this examiner within the Biotechnology & Pharmaceuticals sector. Practitioners should carefully review the feedback from SMITH, EMILIE ALINE to refine their prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, EMILIE ALINE | 1 | 49.4% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17262009 | Method for the Study of Embryo Mutations in IN VITRO Reproduction Processes | SMITH, EMILIE ALINE | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17262009 | Method for the Study of Embryo Mutations in IN VITRO Reproduction Processes | SMITH, EMILIE ALINE | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17262009 | Method for the Study of Embryo Mutations in IN VITRO Reproduction Processes | SMITH, EMILIE ALINE | 1686 | §101§112 | Non-Final OA | 30d overdue | Pending | Jan 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial